

Telmisartan, hydrochlorothiazide (MicardisPlus®) (No. 39/03)

Boehringer Ingelheim

Summary of Recommendation

9 May, 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for restricted use within NHS Scotland.

RECOMMENDATION

Telmisartan / hydrochlorothiazide (MicardisPlus®) has efficacy similar to the antihypertensive effects of the individual constituents added together in the treatment of essential hypertension. No increased costs are associated with this product compared with telmisartan (Micardis®) alone. Angiotensin II receptor antagonists are an alternative to ACE inhibitors where these are not tolerated.

Professor David H Lawson
Chairman